Navigation Links
WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
Date:7/11/2008

SHANGHAI, China, July 11 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has won the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. The Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology is awarded to the company that has demonstrated commendable success in forming strategic partnerships with global clients for outsourced laboratory and research manufacturing services in drug discovery and development in pharmaceuticals and biotechnology.

Quality of scientists and personnel, service portfolio, quality of services, speed of service delivery, cost competitiveness, past experience and referrals are the selection criteria that Frost & Sullivan used. According to Frost & Sullivan, WuXi has excelled in the delivery of high-quality services in a timely manner and at competitive costs through a team of proficient scientists supported by world-class management.

"Until January, 2008, WuXi PharmaTech had provided services to more than 700 global clients, with coverage of pharmaceutical, biotechnology and medical devices. High proportion of repeat and referral customers is a testament to its focus on customer satisfaction and operation excellence," said Frost & Sullivan Leader of China Healthcare Operation Mr. Xuchao Hou. "The main contributing fact
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
2. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
3. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
4. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
5. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
6. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
7. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
8. WuXi PharmaTech Announces First Quarter 2008 Results
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
11. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... University of Minnesota electrical engineering researchers have developed ... time demonstrates mechanical transportation of light. The discovery ... more efficient optical devices for computation and communication. ... electrical and computer engineering assistant professor Mo Li ... published online and will appear in the October ...
(Date:9/22/2014)... Lawrence Livermore National Laboratory Director ... Friday renewed their institutional commitment by signing a ... to expand the collaborative work in the areas ... energy and environmental sciences. , This renewal represents ... in December 2009 and is a framework to ...
(Date:9/22/2014)... YORK , Sept. 22, 2014 US ... US demand for specialty biocides is forecast to rise ... In volume terms, demand is projected to increase 1.3 ... same period. A strong rebound in construction expenditures will ... paint and coatings markets, while growth in consumer spending ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Chitin and chitosan are natural biopolymers available in ... extracted from easily available resources such as shells ... and chitosan is mainly due to the high ... cellulose. Chitosan finds application in various industries owing ...
Breaking Biology Technology:Engineers show light can play seesaw at the nanoscale 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2US Biocides Market 2US Biocides Market 3Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3
... SAN DIEGO, Oct. 15 PURE Bioscience (Nasdaq:,PURE), ... today reported revenues for the fiscal year ended ... 340% compared with $336,400 in the,prior fiscal year. ... taxes,of $(6,540,300), or $(0.24) per share, compared with ...
... Receptor ... CCR9 for Gastrointestinal Diseases, MOUNTAIN VIEW, Calif., ... initiated a Phase I clinical trial of CCX025,the company,s ... inhibits the chemokine receptor known as CCR9.,Structurally distinct from ...
... Oct. 15 The increased emphasis on,safety by ... medical,product development programs and requires rapid, cost-effective and,resource ... effect constructive change can be found in consulting ... clients from compliance errors,that can lead to adverse ...
Cached Biology Technology:PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development 2ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development 3ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development 4Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 3
(Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" ... also suffer an unfortunate side effect, researchers report: ... bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences . ... undesirable consequence of the evolution of antifreeze proteins ...
(Date:9/22/2014)... in this image burn in Khabarovsk Krai, a territory occupying ... hotspots, accompanied by plumes of smoke mark active fires. The ... east towards the Sea of Okhotsk. Taiga and ... forest inhabit the central depression, and deciduous forests are the ... common in Russia in the summer, the 2014 wildfire season ...
(Date:9/22/2014)... greater risk for stress-related diseases like type 2 ... new study by Brandeis University. , It,s long ... similar to the effects of illness or injury, ... part of our body,s healing response, runaway inflammation ... , In a recently published paper in ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Obesity and stress pack a double hit for health 2
... Boston have developed a new nanobiotechnology that enables ... They describe the technology, which could lead to ... January issue of Nature Nanotechnology (published online January ... Mannix, PhD, of Childrens program in Vascular Biology, ...
... transcription -- the intricate transfer of information from a ... RNA -- isn,t stationed in special "transcription factories" within ... enzyme RNA polymerase II (Pol II) and other key ... gene, regardless of the gene,s position., The findings, published ...
... for Biomolecular Sciences (SBS) WHAT: Latest Findings and ... WHEN: April 6-10, 2008 WHERE: SBS ... BACKGROUND: More than 2,500 researchers and professionals ... expected to attend the 14th Annual Conference & Exhibition of ...
Cached Biology News:An 'attractive' man-machine interface 2An 'attractive' man-machine interface 3Research sheds light on the mechanics of gene transcription 2
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
GM130 Immunogen: Recombinant purified rat GM130 Family / Subclass 1: Signal Transduction Storage: 4 C...
... Anti-NY-ESO-1, clone E978 ... : NM_001327 Immunogen ... protein Formulation: mouse ascites ... Quality Assurance: routinely evaluated ...
R26.4C...
Biology Products: